RESOURCE AND PATIENT MANAGEMENT SYSTEM

IHS Clinical Reporting System (BGP)

National GPRA Developmental Report
Performance Measure List and Definitions

Version 10.0
July 2010

Office of Information Technology (OIT)
Division of Information Resource Management
Albuquerque, New Mexico
# Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Revision</th>
<th>Description</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/3/10</td>
<td>N/A</td>
<td>Distribution to field leads for review.</td>
<td>D. Rozsnyai, M. Powers</td>
</tr>
<tr>
<td>3/10/10</td>
<td>1</td>
<td>Revised H1N1 measure.</td>
<td>M. Powers</td>
</tr>
<tr>
<td>3/12/10</td>
<td>2</td>
<td>Added Childhood Immunization measure</td>
<td>M. Powers</td>
</tr>
<tr>
<td>3/19/10</td>
<td>3</td>
<td>Updated H1N1 patient lists</td>
<td>M. Powers</td>
</tr>
<tr>
<td>3/30/10</td>
<td>4</td>
<td>Clarified that any patients that are included in the Demo/Test Patient Search Template for CRS will not be included in the denominators.</td>
<td>M. Powers</td>
</tr>
<tr>
<td>4/13/10</td>
<td>5</td>
<td>Revised H1N1 measure</td>
<td>M. Powers</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

1.0 CRS 2010 National GPRA Developmental Report ................................................. 1
   1.1 CRS Denominator Definitions ............................................................................. 4
      1.1.1 For All Denominators ............................................................................. 4
      1.1.2 For All Numerators ............................................................................... 4
      1.1.3 Active Clinical Population for National GPRA Developmental Reporting .... 4
      1.1.4 Active Clinical Population for Local Reports ......................................... 4
      1.1.5 User Population for National GPRA Developmental Reporting ............... 5
      1.1.6 User Population for Local Reports ......................................................... 5
      1.1.7 Active Clinical CHS Population for National GPRA Developmental Reporting (CHS-only sites) ................................................................. 5
      1.1.8 Active Clinical CHS Population for Local Reports (CHS-only sites) .......... 6

2.0 CRS National GPRA Developmental Report Performance Measure Topics and Definitions ............................................................................................................... 7
   2.1 Dental Group .................................................................................................... 7
      2.1.1 Dental Sealants ....................................................................................... 7
      2.1.2 Topical Fluoride .................................................................................... 8
   2.2 Immunization Group ....................................................................................... 9
      2.2.1 H1N1 Immunization Status ..................................................................... 9
      2.2.2 Childhood Immunizations ...................................................................... 14
   2.3 Cancer Screening Group ................................................................................ 22
      2.3.1 Cancer Screening: Mammogram Rates .................................................. 22
      2.3.2 HEDIS Colorectal Cancer Screening ...................................................... 24
      2.3.3 USPSTF Colorectal Cancer Screening .................................................... 26
      2.3.4 Comprehensive Cancer Screening ......................................................... 28
      2.3.5 Tobacco Cessation ............................................................................... 32
   2.4 Behavioral Health Group ................................................................................. 36
      2.4.1 Alcohol Screening .................................................................................. 36
      2.4.2 Intimate Partner (Domestic) Violence Screening .................................... 38
      2.4.3 Depression Screening ............................................................................ 39
   2.5 Cardiovascular Disease Related Group ............................................................ 41
      2.5.1 Comprehensive CVD-Related Assessment .............................................. 41
   2.6 STD-Related Group ....................................................................................... 45
      2.6.1 HIV Screening ...................................................................................... 45
   2.7 High-Risk Medications Group ........................................................................ 47
      2.7.1 Use of High-Risk Medications in the Elderly ......................................... 47

3.0 Contact Information ............................................................................................ 50
1.0 CRS 2010 National GPRA Developmental Report

The following performance measures will be reported in the Clinical Reporting System (CRS) 2010 National Government Performance and Results Act of 1993 (GPRA) & Program Assessment Rating Tool (PART) Report.

Note: Beginning FY 2010 GPRA Developmental will be reported in its own separate section within the National GPRA and PART report but are not submitted to OMB and Congress. This document contains only the GPRA Developmental performance measure lists and definitions.

**Bold** font indicates GPRA Developmental measures. GPRA Developmental measures have the potential to become a GPRA measures in the future.

*Italic* font indicates changes from CRS version 9.0 Patch 1.

One asterisk prior to the topic (*) indicates NEW GPRA Developmental Measure for 2010

**DENTAL GROUP**

Dental Sealants (6-15 years of age)

* **Intact Dental Sealants**

Topical Fluoride

* **Topical Fluoride Application**

**IMMUNIZATIONS**

H1N1 Immunization Status

* Active Clinical 6-59 months with one dose of H1N1 (no refusals)
* Active Clinical 6-59 months with two doses of H1N1 (no refusals)
* Active Clinical 5-9 years with one dose of H1N1 (no refusals)
* Active Clinical 5-9 years with two doses of H1N1 (no refusals)
* Active Clinical 10-18 years with one dose of H1N1 (no refusals)
* Active Clinical 19-24 years with one dose of H1N1 (no refusals)
* Active Clinical 25-64 years with one dose of H1N1 (no refusals)
* Active Clinical 65+ years with one dose of H1N1 (no refusals)
* Pregnant Active Clinical with one dose of H1N1 (no refusals)
* High-Risk Active Clinical 25-64 years with one dose of H1N1 (no refusals)

Childhood Immunizations (19–35 months)

Active IMM Package Pts w/ 4:3:1:3:1:3:1:4

*3 Pneumococcal
CANCER SCREENING

Mammogram Rates (42+ years of age)
* Mammogram (no refusals)

HEDIS Colorectal Cancer screening (50-75 years of age)
* Fecal Occult Blood Test or Fecal Immunochemical Test during Report Period, Flexible Sigmoidoscopy in past 5 years, or Colonoscopy in past 10 years

USPSTF Colorectal Cancer screening (50-75 years of age)
* Fecal Occult Blood Test or Fecal Immunochemical Test during Report Period, Flexible Sigmoidoscopy in past 5 years AND FOB/ FIT in the past 3 years, or Colonoscopy in past 10 years

Comprehensive Cancer Screening
* Cervical cancer, breast cancer, and/or colorectal cancer screening

Tobacco Cessation
Tobacco Cessation Counseling or Smoking Cessation Aid (no refusals)
Quit Tobacco Use
Tobacco Cessation Counseling or Refusal, Smoking Cessation Aid, or Quit Tobacco Use

BEHAVIORAL HEALTH

Alcohol Screening
* Alcohol Screening, alcohol-related diagnosis or procedure (no refusals)
* Alcohol-related patient education
* Positive alcohol screen

Intimate Partner Violence/Domestic Violence Screening
* Intimate Partner Violence/Domestic Violence Screening (no refusals or patient education)
* IPV/DV-related patient education

Depression Screening
* Depression Screening, Mood Disorder Diagnosis or Suicide Ideation (no refusals)

CARDIOVASCULAR DISEASE-RELATED

Comprehensive CVD-Related Assessment
* BP, LDL, and Tobacco Assessed, BMI (no BMI refusals), and Lifestyle Counseling (no refusals or depression screening)
* Depression screening, mood disorder diagnosis or suicide ideation (no refusals)
* BP documented
* LDL completed
* Tobacco Screen
* BMI calculated (no refusals)
* Received lifestyle education

STD GROUP

HIV Screening
HIV Screening (no refusals)
Refusal of HIV Screening
HIV Screens for User Population with no prior HIV diagnosis

HIGH-RISK MEDICATIONS
Use of High-Risk Medications in the Elderly
Exposure to at least one high-risk medication
Exposure to multiple high-risk medications

Definitions for all GPRA Developmental performance measure topics included in CRS begin in Section 2.0.
1.1 CRS Denominator Definitions

1.1.1 For All Denominators
- All patients with name “DEMO,PATIENT” or who are included in the Demo/Test Patient Search Template for CRS will be excluded automatically for all denominators.
- For all measures, except as noted, patient age is calculated as of the beginning of the report period.

1.1.2 For All Numerators
- For all measures, except as noted, GPRA Developmental Numerators do NOT include refusals or contraindications.

1.1.3 Active Clinical Population for National GPRA Developmental Reporting
- Must have two visits to medical clinics in the past three years. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2010 Clinical Measures User Manual for listing of these clinics.
- Must be alive on the last day of the report period.
- Must be American Indian/Alaska Native (AI/AN)–defined as Beneficiary 01.
- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined Contract Health Service (CHS) catchment area.

1.1.4 Active Clinical Population for Local Reports
- Must have two visits to medical clinics in the past three years. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2010 Clinical Measures User for listing of these clinics.
- Must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both.
User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.1.5 **User Population for National GPRA Developmental Reporting**
- Must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the report period.
- Must be AI/AN–defined as Beneficiary 01.
- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined CHS catchment area.

1.1.6 **User Population for Local Reports**
- Must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.1.7 **Active Clinical CHS Population for National GPRA Developmental Reporting (CHS-only sites)**
- Must have two CHS visits in the three years prior to the end of the report period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the report period.
- Must be AI/AN–defined as Beneficiary 01. This data item is entered and updated during the Patient Registration process.
- Must reside in a community included in the site’s “official” GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy specified by the user.
1.1.8 **Active Clinical CHS Population for Local Reports (CHS-only sites)**

- Must have two CHS visits in the three years prior to the end of the report period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.
2.0 CRS National GPRA Developmental Report Performance Measure Topics and Definitions

The following sections define the performance measure topics and their definitions that are included in the CRS 2010 version 10.0 National GPRA Developmental Report.

Note:  *Bold italic* font indicates new or edited definitions based on previous version of CRS.

2.1 Dental Group

2.1.1 Dental Sealants

This Entire Topic is a New GPRA Developmental

Owner/Contact

Dental Program/Dr. Patrick Blahut

National Reporting

NATIONAL (included in IHS Performance Report; *not* reported to OMB and Congress)

Denominator

1. **GPRA Developmental**: Patients meeting the User Population definition; Ages 6-15.

Numerators

1. **GPRA Developmental**: Patients with at least one or more intact dental sealants.

Definitions

**Intact Dental Sealant**

V Dental ADA code 1351 or V CPT code D1351 documented during the Report Period or V Dental ADA code 0007 or V CPT code D0007 documented during the past three years. *If both ADA and CPT codes are found on the same visit, only the ADA will be counted.*

Patient List Options

List of patients 6-15 with intact dental sealant.

List of patients 6-15 without intact dental sealant.
2.1.2 Topical Fluoride

This Entire Topic is a New GPRA Developmental

Owner/Contact
Dental Program/Dr. Patrick Blahut

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. **GPRA Developmental**: Patients meeting the User Population definition; Ages 2-15.

Numerators
1. **GPRA Developmental**: Patients who received one or more topical fluoride applications during the report period.

Definitions

**Topical Fluoride Application**
- Dental ADA codes 1201 (old code), 1203, 1204, 1205 (old code), 1206 or 5986
- CPT D1203, D1204, D1206, or D5986
- POV V07.31

**Patient List Options**
List of patients 2-15 who received at least one topical fluoride application during report period.
List of patients 2-15 who did NOT received at least one topical fluoride application during report period.
2.2 Immunization Group

2.2.1 H1N1 Immunization Status

This Entire Topic is a New GPRA Developmental

Owner/Contact

Epidemiology Program/Amy Groom, MPH

National Reporting

NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator

1. **GPRA Developmental:** Active Clinical Patients broken down by age groups: 6-59 months, 5-9 years, 10-18 years, 19-24 years, 25-64 years, and 65+ years of age.
2. **GPRA Developmental:** All Active Clinical patients who were pregnant sometime during October 1, 2009 until the end of the Report Period.
3. **GPRA Developmental:** High-Risk Active Clinical Patients 25-64 years of age.

Numerators

1. **GPRA Developmental:** Patients with at least 1 dose of H1N1 vaccine during the Report Period.
2. **GPRA Developmental:** Patients with at least 2 doses of H1N1 vaccine during the Report Period.\(^1\)

Definitions

**H1N1 Immunization**

Any of the following documented during the report period:

- CVX codes 125 Live Nasal, 126 Injectable-Preservative Free, 127 Injectable, 128 All formulations
- CPT 90470, 90663, 90664, 90666-90668, G9141 or G9142

**H1N1 Second Dose Inclusion**

The second dose must be received at least 21 days after the first dose and both doses must be received during the Report Period.

\(^1\) Included only with denominators of 6-59 months and 5-9 years of age.
Pregnancy

Having a Pregnancy POV (Ambulatory, Hospitalization or In-Hospital) between the time period of October 1, 2009 and the end of the Report Period. The patient must not have a documented abortion or miscarriage occurring after the pregnancy-related visit.

Pregnancy:

- POV 640.00, 640.03, 640.80, 640.83, 640.90, 640.93, 641.00, 641.03, 641.10, 641.13, 641.20, 641.23, 641.30, 641.33, 641.80, 641.83, 641.90, 641.93, 642.00, 642.03, 642.10, 642.13, 642.20, 642.23, 642.30, 642.33, 642.40, 642.43, 642.50, 642.53, 642.60, 642.63, 642.70, 642.73, 642.90, 642.93, 643.00, 643.03, 643.10, 643.13, 643.20, 643.23, 643.80, 643.83, 643.90, 643.93, 644.00, 644.03, 644.10, 644.13, 645.00, 645.03, 645.10, 645.13, 645.20, 645.23, 646.00, 646.03, 646.10, 646.13, 646.20, 646.23, 646.30, 646.33, 646.40, 646.43, 646.50, 646.53, 646.60, 646.63, 646.70, 646.73, 646.80, 646.83, 646.90, 646.93, 647.00, 647.03, 647.10, 647.13, 647.20, 647.23, 647.30, 647.33, 647.40, 647.43, 647.50, 647.53, 647.60, 647.63, 647.80, 647.83, 647.90, 647.93, 648.00, 648.03, 648.10, 648.13, 648.20, 648.23, 648.30, 648.33, 648.40, 648.43, 648.50, 648.53, 648.60, 648.63, 648.70, 648.73, 648.80, 648.83, 648.90, 649.00, 649.03, 649.10, 649.13, 649.20, 649.23, 649.30, 649.33, 649.40, 649.43, 649.50, 649.53, 649.60, 649.63, 649.70, 649.73, 651.00, 651.03, 651.10, 651.13, 651.20, 651.23, 651.30, 651.33, 651.40, 651.43, 651.50, 651.53, 651.60, 651.63, 651.70, 651.73, 651.80, 651.83, 651.90, 651.93, 652.00, 652.03, 652.10, 652.13, 652.20, 652.23, 652.30, 652.33, 652.40, 652.43, 652.50, 652.53, 652.60, 652.63, 652.70, 652.73, 652.80, 652.83, 652.90, 652.93, 653.00, 653.03, 653.10, 653.13, 653.20, 653.23, 653.30, 653.33, 653.40, 653.43, 653.50, 653.53, 653.60, 653.63, 653.70, 653.73, 653.80, 653.83, 653.90, 653.93, 654.00, 654.03, 654.10, 654.13, 654.20, 654.23, 654.30, 654.33, 654.40, 654.43, 654.50, 654.53, 654.60, 654.63, 654.70, 654.73, 654.80, 654.83, 654.90, 654.93, 655.00, 655.03, 655.10, 655.13, 655.20, 655.23, 655.30, 655.33, 655.40, 655.43, 655.50, 655.53, 655.60, 655.63, 655.70, 655.73, 655.80, 655.83, 655.90, 655.93, 656.00, 656.03, 656.10, 656.13, 656.20, 656.23, 656.30, 656.33, 656.40, 656.43, 656.50, 656.53, 656.60, 656.63, 656.70, 656.73, 656.80, 656.83, 656.90, 656.93, 657.00, 657.03, 658.00, 658.03, 658.10, 658.13, 658.20, 658.23, 658.30, 658.33, 658.40, 658.43, 658.80, 658.83, 658.90, 658.93, 659.00, 659.03, 659.10, 659.13, 659.20, 659.23, 659.30, 659.33, 659.40, 659.43, 659.50, 659.53, 659.60, 659.63, 659.70, 659.73, 659.80, 659.83, 659.90, 659.93, 660.00, 660.03, 660.10, 660.13, 660.20, 660.23, 660.30, 660.33, 660.40, 660.43, 660.50, 660.53, 660.60, 660.63, 660.70, 660.73, 660.80, 660.83, 660.90, 660.93, 661.00, 661.03, 661.10, 661.13, 661.20, 661.23, 661.30, 661.33, 661.40, 661.43, 661.90, 661.93, 662.00, 662.03, 662.10, 662.13, 662.20, 662.23, 662.30, 662.33, 663.00, 663.03, 663.10, 663.13, 663.20, 663.23, 663.30,
663.33, 663.40, 663.43, 663.50, 663.53, 663.60, 663.63, 663.80, 663.83, 663.90, 663.93, 665.00, 665.03, 665.80, 665.83, 665.90, 665.93, 671.00, 671.03, 671.10, 671.13, 671.20, 671.23, 671.30, 671.33, 671.50, 671.53, 671.80, 671.83, 671.90, 671.93, 673.00, 673.03, 673.10, 673.13, 673.20, 673.23, 673.30, 673.33, 673.80, 673.83, 675.00, 675.03, 675.80, 675.83, 675.90, 675.93, 671.08, 671.18, 671.28, 671.38, 671.48, 671.58, 671.68, 671.78, 671.88, 671.98, 673.08, 673.18, 673.28, 673.38, 673.48, 673.58, 673.68, 673.78, 673.88, V22.0 – V23.9, V72.42

### Miscarriage

- POV 630, 631, 632, 633*, 634*
- CPT 59812, 59820, 59821, 59830

### Abortion

- POV 635*, 636* 637*
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267
- Procedure 69.01, 69.51, 74.91, 96.49

### High-Risk Patients

Persons who have a high-risk condition for flu defined as those 25 to 64 years who have 2 or more visits in the past 3 years with a POV or Problem diagnosis of any of the following:

- HIV Infection (042, 042.0-044.9 (old codes))
- Diabetes (250.00-250.93)
- Rheumatic Heart Disease (393.-398.99)
- Hypertensive Heart Disease (402.00-402.91)
- Hypertensive Heart/Renal Disease (404.00-404.93)
- Ischemic Heart Disease (410.00-414.9)
- Pulmonary Heart Disease (415.0-416.9)
- Other Endocardial Heart Disease (424.0-424.9)
- Cardiomyopathy (425.0-425.9)
- Congestive Heart Failure (428.0-428.9, 429.2)
- Chronic Bronchitis (491.0-491.9)
- Emphysema (492.0-492.8)
- Asthma (493.00-493.91)
- Bronchiectasis, CLD, COPD (494.0-496.)
- Pneumoconioses (500-505)
- Chronic Liver Disease (571.0-571.9)
- Nephrotic Syndrome (581.0-581.9)
- Renal Failure (585.6, 585.9)
- Transplant (996.80-996.89)
- Kidney Transplant (V42.0-V42.89)
- Chemotherapy (V58.1)
- Chemotherapy follow-up (V67.2)

**Patient List Options**

List of Active Clinical patients ages 6-59 months with at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 6-59 months without at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 6-59 months with at least two doses of the H1N1 immunization.

List of Active Clinical patients ages 6-59 months without at least two doses of the H1N1 immunization.

List of Active Clinical patients ages 5-9 years with at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 5-9 years without at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 5-9 years with at least two doses of the H1N1 immunization.

List of Active Clinical patients ages 5-9 years without at least two doses of the H1N1 immunization.

List of Active Clinical patients ages 10-18 years with at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 10-18 years without at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 19-24 years with at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 19-24 years without at least one dose of the H1N1 immunization.
List of Active Clinical patients ages 25-64 years with at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 25-64 years without at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 65+ years with at least one dose of the H1N1 immunization.

List of Active Clinical patients ages 65+ years without at least one dose of the H1N1 immunization.

List of Active Clinical pregnant patients with no documented miscarriage or abortion with at least one dose of the H1N1 immunization.

List of Active Clinical pregnant patients with no documented miscarriage or abortion without at least one dose of the H1N1 immunization.

List of Active Clinical ages 25-64 who have a high-risk condition for flu with at least one dose of the H1N1 immunization.

List of Active Clinical ages 25-64 who have a high-risk condition for flu without at least one dose of the H1N1 immunization.
2.2.2 Childhood Immunizations

Moved from GPRA to GPRA Developmental for 2010

Owner/Contact
Epidemiology Program/Amy Groom, MPH

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominators
1. **GPRA:** User Population patients active in the Immunization Package who are 19–35 months at end of report period.

   **Note:** Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

Numerator
1. **GPRA Developmental:** Patients who have received the 4:3:1:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), including contraindications and evidence of disease.

   **Note:** The only refusals included in this numerator are documented NMI (not medically indicated) refusals.

2. Patients who have received 3 doses of Pneumococcal conjugate vaccine ever, including contraindications and evidence of disease.

   **Note:** The only refusals included in this numerator are documented NMI (not medically indicated) refusals.

Definitions

**Patient Age**
Since the age of the patient is calculated at the beginning of the report period, the age range will be adjusted to 7–23 months at the beginning of the report period, which makes the patient between the ages of 19–35 months at the end of the report period.

**Timing of Doses**
Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.
Active Immunization Package Patients Denominator

Same as User Population definition except includes only patients flagged as active in the Immunization Package.

Dosage and Types of Immunizations

- **4 Doses of DTaP**
  - 4 DTaP/DTP/Tdap
  - 1 DTaP/DTP/Tdap and 3 DT/Td
  - 1 DTaP/DTP/Tdap and 3 each of Diphtheria and Tetanus
  - 4 DT and 4 Acellular Pertussis
  - 4 Td and 4 Acellular Pertussis
  - 4 each of Diphtheria, Tetanus, and Acellular Pertussis

- **3 Doses of Polio**
  - 3 OPV
  - 3 IPV; or
  - Combination of OPV & IPV totaling 3 doses

- **1 Dose of MMR**
  - MMR
  - 1 M/R and 1 Mumps
  - 1 R/M and 1 Measles; or
  - 1 each of Measles, Mumps, and Rubella

- **3 doses of Hep B OR 2 doses IF documented with CPT 90743**

- **3 doses of HIB**

- **1 dose of Varicella**

- **4 doses of Pneumococcal**

**Not Medically Indicated (NMI) refusals, Contraindication, and Evidence of Disease Information**

- Not Medically Indicated (NMI) refusals, evidence of disease, and contraindications for individual immunizations will also count toward meeting the definition, as defined below.

**Note:** Not Medically Indicated (NMI) refusals are NOT counted as refusals; rather, they are counted as contraindications.
• To be counted as evidence of disease/contraindication/NMI refusal, a patient must have evidence of disease, a contraindication, or an NMI refusal for any of the immunizations in the numerator. For example, if a patient was Rubella immune but had a Measles and Mumps immunization, the patient would be counted as having evidence of disease for MMR.

• For immunizations where required number of doses is >1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.

• Evidence of disease will be checked for at any time in the child’s life (prior to the end of the report period.).

Refusal Definitions
PCC Refusal type NMI for IZ codes
• **DTaP**: 20, 50, 106, 107, 110, 120, 130
• **DTP**: 1, 22, 102
• **Tdap**: 115; **DT**: 28
• **Td**: 9, 113
• **Tetanus**: 35, 112
• **Acellular Pertussis**: 11
• **OPV**: 2, 89
• **IPV**: 10, 89, 110, 120, 130
• **MMR**: 3, 94
• **M/R**: 4
• **R/M**: 38
• **Measles**: 5
• **Mumps**: 7
• **Rubella**: 6;
• **HiB**: 17, 22, 46-49; 50, 51, 102, 120
• **Hepatitis B**: 8, 42-45, 51, 102, 104, 110
• **Varicella**: 21, 94
• **Pneumococcal**: 33, 100, 109
Immunization Definitions

- **DTaP**
  - Immunization (CVX) codes 20, 50, 106, 107, 110, 120, 130
  - POV V06.1
  - CPT 90696, 90698, 90700, 90721, 90723

- **DTaP Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

- **DTP**
  - Immunization (CVX) codes 1, 22, 102
  - POV V06.1, V06.2, V06.3
  - CPT 90701, 90711 (old code), 90720
  - Procedure 99.39

- **DTP Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

- **Tdap**
  - Immunization (CVX) code 115
  - CPT 90715

- **Tdap Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

- **DT**
  - Immunization (CVX) code 28
  - POV V06.5
  - CPT 90702

- **DT Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

- **Td**
  - Immunization (CVX) code 9, 113
  - POV V06.5
  - CPT 90714, 90718

- **Td Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

- **Diphtheria**
  - POV V03.5
  - CPT 90719
- Procedure 99.36

**Diphtheria Contraindication Definition**
- Immunization Package contraindication of “Anaphylaxis.”

**Tetanus**
- Immunization (CVX) codes 35, 112
- POV V03.7
- CPT 90703
- Procedure 99.38

**Tetanus Contraindication Definition**
- Immunization Package contraindication of “Anaphylaxis.”

**Acellular Pertussis**
- Immunization (CVX) code 11
- POV V03.6
- Procedure 99.37 (old code)

**Acellular Pertussis contraindication definition**
- Immunization Package contraindication of “Anaphylaxis.”

**OPV**
- Immunization (CVX) codes 2, 89;
- CPT 90712

**OPV Contraindication Definition**
- POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204-208; or
- Immunization Package contraindication of “Anaphylaxis.”

**IPV**
- Immunization (CVX) codes 10, 89, 110, 120, 130
- POV V04.0, V06.3
- CPT 90696, 90698, 90711 (old code), 90713, 90723
- Procedure 99.41

**IPV Evidence of Disease Definition**
- POV or PCC Problem List (active or inactive) 730.70-730.79

**IPV contraindication definition**
- Immunization Package contraindication of “Anaphylaxis” or “Neomycin Allergy.”

**MMR**
- Immunization (CVX) codes 3, 94
- POV V06.4
- CPT 90707, 90710
- Procedure 99.48

- **MMR Contraindication Definitions**
  - POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204-208; or
  - Immunization Package contraindication of “Anaphylaxis,” “Immune Deficiency,” “Immune Deficient,” or “Neomycin Allergy.”

- **M/R**
  - Immunization (CVX) code 4
  - CPT 90708

- **M/R Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

- **R/M**
  - Immunization (CVX) code 38
  - CPT 90709 (old code)

- **R/M Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

- **Measles**
  - Immunization (CVX) code 5
  - POV V04.2
  - CPT 90705
  - Procedure 99.45

- **Measles Evidence of Disease Definition**
  - POV or PCC Problem List (active or inactive) 055*

- **Measles Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

- **Mumps**
  - Immunization (CVX) code 7
  - POV V04.6
  - CPT 90704
  - Procedure 99.46

- **Mumps Evidence of Disease Definition**
  - POV or PCC Problem List (active or inactive) 072*

- **Mumps Contraindication Definition**
Immunization Package contraindication of “Anaphylaxis.”

**Rubella**
- Immunization (CVX) code 6
- POV V04.3
- CPT 90706
- Procedure 99.47

**Rubella Evidence of Disease Definitions**
- POV or PCC Problem List (active or inactive) 056*, 771.0

**Rubella Contraindication Definition**
- Immunization Package contraindication of “Anaphylaxis.”

**HiB**
- Immunization (CVX) codes 17, 22, 46-49, 50, 51, 102, 120
- POV V03.81
- CPT 90645-90648, 90698, 90720-90721, 90737 (old code), 90748

**HiB Contraindication Definition**
- Immunization Package contraindication of “Anaphylaxis.”

**Hepatitis B**
- Immunization (CVX) codes 8, 42-45, 51, 102, 104, 110
- CPT 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q0010, Q3021 (old code), Q3023 (old code)

**Hepatitis B Evidence of Disease Definition**
- POV or PCC Problem List (active or inactive) V02.61, 070.2, 070.3.

**Hepatitis B Contraindication Definition**
- Immunization Package contraindication of “Anaphylaxis.”

**Varicella**
- Immunization (CVX) codes 21, 94
- POV V05.4
- CPT 90710, 90716

**Varicella Evidence of Disease Definition**
- POV or PCC Problem List (active or inactive) 052*, 053*; or
- Immunization Package contraindication of “Hx of Chicken Pox” or “Immune.”

**Varicella Contraindication Definitions**
- POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204-208; or
- Immunization Package contraindication of “Anaphylaxis,” “Immune Deficiency,” “Immune Deficient,” or “Neomycin Allergy.”

- **Pneumococcal**
  - Immunization (CVX) codes 33 Pneumo Polysaccaride; 100 Pneumo Conjugate; 109 Pneumo NOS, 133 Pneumo Conjugate
  - POV V06.6; V03.82
  - CPT 90669, 90670, 90732, G0009, G8115

- **Pneumococcal Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis.”

**Patient List Options**

**Note:** Because age is calculated at the beginning of the report period, the patient's age on the list will be between 7–23 months.

List of Active Immunization Package patients 19-35 months who received the 4:3:1:3:3:1:4 combination (4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hep B, 1 Varicella, and 4 Pneumococcal).

List of patients Active Immunization Package patients 19-35 months who have not received the 4:3:1:3:3:1:4 combination (4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hep B, 1 Varicella and 4 Pneumococcal). If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP.
2.3 Cancer Screening Group

2.3.1 Cancer Screening: Mammogram Rates

This Entire Topic is a New GPRA Developmental

Owner/Contact
Carolyn Aoyama

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. GPRA Developmental: Female Active Clinical patients ages 42 and older without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

Note: The patients must be at least 42 years of age as of the beginning of the Report Period.

Numerators
1. GPRA Developmental: All patients who had a Mammogram documented in the past 2 years.

Definitions

Bilateral Mastectomy
- CPT 19300.50-19307.50 OR 19300-19307 w/modifier 09950 (.50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, or 19240, w/modifier of .50 or 09950; or
- ICD Operation codes 85.42; 85.44; 85.46; 85.48

Unilateral Mastectomy
Requires two separate occurrences for either CPT or procedure codes on 2 different dates of service.
- CPT 19300-19307, or old codes 19180, 19200, 19220, 19240 or
- Procedures 85.41, 85.43, 85.45, 85.47

Mammogram
- V Radiology or CPT 77053-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202
- POV V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89. Other abnormal findings on radiological exam of breast
- Procedures 87.36, 87.37
- Women’s Health Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have “ERROR/DISREGARD.”

**Patient List Options**

List of female patients 42 and older with a Mammogram documented in the past 2 years.

List of female patients 42 and older without a Mammogram documented in the past 2 years.
2.3.2 HEDIS Colorectal Cancer Screening

This Entire Topic is a New GPRA Developmental

Note: Based on the HEDIS definition which has lowered the upper age from 80 to 75.
Numerator does not include DCBE.

Owner/Contact
Epidemiology Program/ Dr. Nathaniel Cobb

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. GPRA Developmental: Active Clinical patients ages 50-75 without a documented history of colorectal cancer or total colectomy, broken out by gender.

Note: Since HEDIS calculates age at the end of the report period. The patient’s at the beginning of the report period must be at least 50 years of age and 51 years of age at the end of the report period.

Numerators
1. GPRA Developmental: Patients who have had ANY CRC screening, defined as any of the following:
   A. Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the Report Period;
   B. Flexible sigmoidoscopy in the past 5 years; or
   C. Colonoscopy in the past 10 years.

Definitions

Denominator Exclusions
Any diagnosis ever of one of the following:

Colorectal Cancer
- POV 153.*, 154.0, 154.1, 197.5, V10.05
- CPT G0213-G0215, G0231

Total Colectomy
- CPT 44150-44151, 44152 (old code), 44153 (old code), 44155-44158, 44210-44212
- Procedure 45.8 (old code)
Colorectal Cancer Screening  
The most recent of any of the following during applicable timeframes:

- **FOBT or FIT**
  - POV V76.51 Colon screening
  - CPT 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)
  - LOINC taxonomy; or
  - Site-populated taxonomy BGP GPRA FOB TESTS

- **Flexible Sigmoidoscopy**
  - Procedure 45.24; CPT 45330-45345, G0104

- **Colonoscopy**
  - Procedure 45.22, 45.23, 45.25, 45.42, 45.43
  - CPT 44388-44394, 44397, 45355, 45378-45387, 45391, 45392, G0105, G0121

**Patient List Options**

List of patients 50-75 with CRC screening (HEDIS definition).

List of patients 50-75 without CRC screening (HEDIS definition)
2.3.3 USPSTF Colorectal Cancer Screening

This Entire Topic is a New GPRA Developmental

| Note: Based on the United States Preventive Services Task Force (USPSTF) 2008 recommendations and which uses the HEDIS codes for the different types of screening. This definition is different from the GPRA definition for both the denominator and numerator. |
| Denominator does NOT include exclusions for patients with a diagnosis of colorectal cancer or total colectomy and the numerator does not include DCBE. |

Owner/Contact
Epidemiology Program/ Dr. Nathaniel Cobb

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. **GPRA Developmental:** Active Clinical patients ages 50-75, broken out by gender.

Numerators
1. **GPRA Developmental:** Patients who have had ANY CRC screening, defined as any of the following:
   A. Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the Report Period;
   B. Flexible sigmoidoscopy in the past 5 years AND FOB/ FIT in the past 3 years; or
   C. Colonoscopy in the past 10 years.

Definitions

Colorectal Cancer Screening
The most recent of any of the following during applicable timeframes:

- **FOBT or FIT**
  - POV V76.51 Colon screening
  - CPT 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)
  - LOINC taxonomy; or site-populated taxonomy BGP GPRA FOB TESTS
- **Flexible Sigmoidoscopy**
  - Procedure 45.24
  - CPT 45330-45345, G0104
- **Colonoscopy**
  - Procedure 45.22, 45.23, 45.25, 45.42, 45.43
  - CPT 44388-44394, 44397, 45355, 45378-45387, 45391, 45392, G0105, G0121

**Patient List Options**

List of patients 50-75 with CRC screening (USPSTF definition).

List of patients 50-75 without CRC screening (USPSTF definition).
2.3.4 Comprehensive Cancer Screening

This Entire Topic is a New GPRA Developmental

Owner/Contact
Epidemiology Program/ Dr. Nathaniel Cobb, Carolyn Aoyama

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominators
1. **GPRA Developmental**: Active Clinical patients ages 21-75 who are eligible for cervical cancer, breast cancer, and/or colorectal cancer screening, broken down by age groups and gender: 21-75, Female 21-75, Male 50-75.

Numerators
1. **GPRA Developmental**: Patients who have had all screenings for which they are eligible.
2. Female patients with cervical cancer, breast cancer, and/or colorectal cancer screening.
3. Male patients with colorectal cancer screening.

Definitions

**Cervical Cancer Screening**
To be eligible for this screening:
- Patients must be female Active Clinical ages 21 through 64 and not have a documented history of hysterectomy.
- Patients must be at least 21 years of age at the beginning of the Report Period and less than 65 years of age as of the end of the Report Period.
- To be counted as having the screening, the patient must have had a Pap Smear documented in the past 3 years.

**Hysterectomy**
Any of the following ever:
- Procedure 68.4-68.8
- CPT 51925, 56308 (old code), 58150, 58152, 58200-58294, 58548, 58550-58554, 58570-58573, 58951, 58953-58954, 58956, 59135
- POV 618.5, V88.01, V88.03; or
- Women's Health procedure called Hysterectomy
Pap Smear
- V Lab Pap Smear
- POV V67.01 Follow-up Vaginal Pap Smear, V76.2 Screen Mal Neop-Cervix, V72.31 Routine Gynecological Examination, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, V72.3 Gynecological Examination, Pap Cervical Smear as Part of General Gynecological Exam, Pelvic Exam (annual) (periodic) (old code, to be counted for visits prior to 10/1/04 only), V76.47 Vaginal Pap Smear for Post-Hysterectomy Patients, 795.0*, 795.10-16, 795.19
- Procedure 91.46
- CPT 88141-88167, 88174-88175, G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091
- Women’s Health procedure called Pap Smear
- LOINC taxonomy
- Site-populated taxonomy BGP PAP SMEAR TAX

Breast Cancer Screening
To be eligible for this screening:
- Patients must be female Active Clinical ages 52 through 64 and not have a documented history ever of bilateral mastectomy or two separate unilateral mastectomies.
- Patients must be at least age 52 as of the beginning of the Report Period and must be less than 65 years of age as of the end of the Report Period.
- To be counted as having the screening, the patient must have had a Mammogram documented in the past 2 years

Bilateral mastectomy
Any of the following ever:
- CPT 19300.50-19307.50 OR 19300-19307 w/modifier 09950 (.50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, or 19240, w/modifier of .50 or 09950
- ICD Operation codes 85.42; 85.44; 85.46; 85.48

Unilateral mastectomy
Must have 2 separate occurrences for either CPT or procedure codes on 2 different dates of service:
- CPT 19300-19307, or old codes 19180, 19200, 19220, 19240
- ICD Operation codes 85.41, 85.43, 85.45, 85.47
Screening Mammogram
- V Radiology or CPT 77053-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206; G0204, G0202
- POV V76.11 screening mammogram for high risk patient; V76.12 other screening mammogram; 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast
- Procedure 87.36 Xerography of breast, 87.37 Other Mammography
- Women's Health Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD"

Colorectal Cancer Screening
To be eligible for this screening:
- Patients must be Active Clinical ages 50-75 and not have a documented history ever of colorectal cancer or total colectomy
To be counted as having the screening, patients must have had any of the following:
- Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the Report Period
- Flexible sigmoidoscopy in the past 5 years; or
- Colonoscopy in the past 10 years

Colorectal Cancer
- POV 153.*, 154.0, 154.1, 197.5, V10.05
- CPT G0213-G0215, G0231

Total Colectomy
- Procedure 45.8 (old code)
- CPT 44150-44151, 44152 (old code), 44153 (old code), 44155-44158, 44210-44212

Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT)
- POV V76.51 Colon screening
- CPT 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)
- LOINC taxonomy; or
- Site-populated taxonomy BGP GPRA FOB TESTS
Flexible Sigmoidoscopy
- Procedure 45.24
- CPT 45330-45345, G0104

Colonoscopy
- Procedure 45.22, 45.23, 45.25, 45.42, 45.43
- CPT 44388-44394, 44397, 45355, 45378-45387, 45391, 45392, G0105, G0121

Patient List Options
- List of patients 21-75 with comprehensive cancer screening.
- List of patients 21-75 without comprehensive cancer screening.
- List of Female patients 21-75 with cervical cancer, breast cancer, and/or colorectal cancer screening.
- List of Female patients 21-75 without cervical cancer, breast cancer, and/or colorectal cancer screening.
- List of Male patients 50-75 with colorectal cancer screening.
- List of Male patients 50-75 without colorectal cancer screening.
2.3.5 Tobacco Cessation

Moved from ONM to GPRA Developmental for 2010

Owner/Contact
Mary Wachacha and Chris Lamer, PharmD/Epidemiology Program, Dr. Nat Cobb

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. **GPRA Developmental**: Active clinical patients identified as current tobacco users or tobacco users in cessation, broken down by gender and age groups: <12, 12-17, 18 and older.

Numerators
1. **GPRA Developmental**: Patients who have received tobacco cessation counseling or received a prescription for a smoking cessation aid anytime during the period 180 days prior to the Report Period through the end of the Report Period.
2. Patients identified as having quit their tobacco use anytime during the period 180 days prior to the Report Period through the end of the Report Period.
   A. Patients whose tobacco use was in cessation and are considered to have quit.
3. **GPRA Developmental**: Patients who received tobacco cessation counseling, received a prescription for a tobacco cessation aid, or quit their tobacco use anytime during the period 180 days prior to the Report Period through the end of the Report Period.

Definitions

**Denominator**
Current Tobacco Users or Tobacco Users in Cessation:

CRS will search first for the last (i.e., most recent) health factor documented during the period 180 days prior to the Report Period through the first 180 days of the Report Period.

If a Tobacco User Health Factor (TUHF) is found and at least one of them is one of the health factors listed below, the patient is counted as a tobacco user in cessation and is also counted as having quit their tobacco use. The patient is not counted as receiving cessation counseling:

- Cessation-Smoker
- Cessation-Smokeless
If a Tobacco User Health Factor (TUHF) is found and at least one of them is one of the health factors listed below, the patient is counted as a tobacco user:

- Current Smoker
- Current Smokeless
- Current Smoker and Smokeless

If a health factor is found and it is NOT a TUHF, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a tobacco user. If one of these codes is not found, the patient is considered a non-tobacco user and will not be included in the denominator.

If no health factor was found during the specified timeframe, CRS will then search for the most recent health factor documented during an EXPANDED timeframe of anytime prior to the report period through the first 180 days of the report period. For example, a patient with the most recent health factor being documented five years prior to the report period.

**Note:** If multiple health factors were documented on the same date and if any of them are TUHF(s), all of the health factors will be considered as TUHF(s).

If a health factor is found during the expanded timeframe and it is not one of the TUHFs, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a tobacco user. If one of these codes is not found, the patient is considered a non-tobacco user and will not be included in the denominator.

If a health factor is found during the expanded timeframe, and is a TUHF, CRS will then search for POV or current Active Problem List diagnosis code 305.13 Tobacco use in remission (old code) or V15.82 with a date occurring after the health factor date and through the first 180 days of the report period. If one of these diagnoses is found, the patient will be considered as having quit their tobacco use and will not be included in the denominator. If a diagnosis is not found, the patient is included as a current tobacco user and will be included in the denominator.

If no health factor was found, CRS will then search for any of the following codes documented during the period 180 days prior to the Report Period through the first 180 days of the Report Period:

- Tobacco-related POV or active Problem List diagnoses 305.1, 305.10-305.12 (old codes), or 649.00-649.04.
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455, G8456, G8402 or G8453.

If any of these codes are found, the patient will be considered a tobacco user. If one of these codes is not found, the patient is considered a non-tobacco user and will not be included in the denominator.

**Tobacco Cessation Counseling**
Any of the following documented anytime during the period 180 days prior to the Report Period through the end of the Report Period:

- Patient education codes containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), or 649.00-649.04
- Clinic code 94 (tobacco cessation clinic)
- Dental code 1320
- CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 or G8453

**Prescription for Tobacco Cessation Aid**
Any of the following documented anytime during the period 180 days prior to the Report Period through the end of the Report Period:

- Prescription for medication in the site-populated BGP CMS SMOKING CESSATION MEDS taxonomy
- Prescription for any medication with name containing “NICOTINE PATCH”, “NICOTINE POLACRILEX”, “NICOTINE INHALER”, or “NICOTINE NASAL SPRAY”
- CPT 4001F

**Quit Tobacco Use**
Any of the following documented anytime during the period 180 days prior to the Report Period through the end of the Report Period AND after the date of the code found indicating the patient was a current tobacco user:

- POV or current Active Problem List diagnosis code 305.13 Tobacco use in remission (old code) or V15.82;
- Health Factor (looks at the last documented health factor): Previous Smoker, Previous Smokeless

**Patient List Options**
List of tobacco users with documented tobacco cessation intervention.

List of tobacco users without documented tobacco cessation intervention.
List of tobacco users who quit tobacco use.

List of tobacco users who did not quit tobacco use.

List of tobacco users with documented tobacco cessation intervention or who quit their tobacco use.

List of tobacco users without documented tobacco cessation intervention and did not quit their tobacco use.
2.4 Behavioral Health Group

2.4.1 Alcohol Screening

This Entire Topic is a New GPRA Developmental

Owner/Contact
Dr. Peter Stuart

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. **GPRA**: Female Active Clinical patients ages 15 to 44 years of age.
2. **GPRA Developmental**: Active Clinical patients ages 12 to 75, broken down by age groups: 12-19, 20-24, 25-34, 35-44, 45-54, and 55-75

Numerators
1. **GPRA Developmental**: Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period.

   **Note**: This numerator does not include alcohol-related patient education.

2. Patients with alcohol-related patient education during the Report Period.
3. **GPRA Developmental**: Patients who were screened positive for alcohol use.

Definitions

**Alcohol Screening**
Any of the following during the Report Period:
- PCC Exam code 35
- Any CAGE Health Factor
- Screening Diagnosis V11.3; V79.1, or BHS problem code 29.1
- CPT 99408, 99409, G0396, G0397, H0049, H0050
- V Measurement in PCC or BH of AUDT, AUDC, or CRFT

**Alcohol-Related Diagnosis or Procedure**
Any of the following during the Report Period:
- Alcohol-related diagnosis:
  - POV, current PCC or BHS Problem List 303.*, 305.0*, 291.*, 357.5*;
  - BHS POV 10, 27, 29;
- BHS Problem Codes 10, 12.1, 14.2, 17.1, 18.1, 20.1, or 22.1
- Alcohol-related procedure (V Procedure) 94.46, 94.53, 94.61-94.63, 94.67-94.69

**Alcohol-Related Patient Education**

Any of the following during the Report Period:

- Patient education codes containing "AOD-" or "-AOD", "CD-" or "-CD" (old codes), or V11.3, V79.1, 303.*, 305.0*, 291.* or 357.5*

**Positive Screen for Alcohol Use**

Any of the following for patients with alcohol screening:

- Exam Code 35 Alcohol Screening result of “Positive”
- Health factor of CAGE result of 1/4, 2/4, 3/4 or 4/4
- CPT G0396, G0397, 99408, or 99409; or
- AUDT result of =>8, AUDE result of =>4 for men and =>3 for women, CRFT result of 2-6

**Patient List Options**

List of female Active Clinical patients 15-44 with documented screening.
List of female Active Clinical patients 15-44 without documented screening.
List of female Active Clinical patients 15-44 with a positive alcohol screen.
List of female Active Clinical patients 15-44 with a negative alcohol screen.
List of Active Clinical patients 12-75 with documented alcohol screening.
List of Active Clinical patients 12-75 without documented alcohol screening.
List of Active Clinical patients 12-75 with a positive alcohol screen.
List of Active Clinical patients 12-75 with a negative alcohol screen.
2.4.2 Intimate Partner (Domestic) Violence Screening

This Entire Topic is a New GPRA Developmental

Owner/Contact
Denise Grenier, LCSW and Dr. Peter Stuart

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. **GPRA**: Female Active Clinical patients ages 15-40.

Nominators
1. **GPRA Developmental**: Patients with an IPV/DV exam or IPV/DV-related diagnosis, procedure, or counseling any time during the Report Period.
   
   **Note**: This numerator does not include IPV/DV-related patient education.

2. Patients with IPV/DV-related education during the Report Period

Definitions

**IPV/DV Exam**
- PCC Exam code 34; or
- BHS IPV/DV exam

**IPV/DV Related Diagnosis**
- POV, Current PCC or BHS Problem List 995.80-83, 995.85 (adult maltreatment), V15.41, V15.42, V15.49 (history of abuse)
- BHS POV 43.*, 44.*

**IPV/DV Patient Education**
- Patient Education codes containing "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, or V15.49

**IPV/DV Counseling**
- POV V61.11

Patient List Options
- List of female patients 15-40 with documented IPV/DV screening.
- List of female patients 15-40 without documented IPV/DV screening.
### 2.4.3 Depression Screening

**This Entire Topic is a New GPRA Developmental**

**Owner/Contact**
Denise Grenier, LCSW and Drs. David Sprenger and Peter Stuart

**National Reporting**
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

**Denominator**
1. **GPRA**: Active Clinical patients ages 18 and older.
2. **GPRA Developmental**: Active Clinical patients ages 12-18.

**Numerators**
1. **GPRA Developmental**: Patients screened for depression or diagnosed with a mood disorder or suicide ideation at any time during the Report Period.

**Definitions**

**Depression Screening**
Any of the following:
- Exam Code 36
- POV V79.0
- BHS problem code 14.1 (screening for depression), or
- V Measurement in PCC or BH of PHQ2 or PHQ9

**Mood Disorders**
At least two visits in PCC or BHS during the Report period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.

- These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311; or BHS POV 14 or 15

**Suicide Ideation**
- POV V62.84; or
- BHS Problem Code 39 during the Report Period
Patient List Options

List of Active Clinical patients =>18 screened for depression/diagnosed with mood disorder or suicide ideation.

List of Active Clinical patients =>18 not screened for depression/diagnosed with mood disorder or suicide ideation.

List of Active Clinical patients 12-18 screened for depression/diagnosed with mood disorder or suicide ideation.

List of Active Clinical patients 12-18 not screened for depression/diagnosed with mood disorder or suicide ideation.
2.5 Cardiovascular Disease Related Group

2.5.1 Comprehensive CVD-Related Assessment

This Entire Topic is a New GPRA Developmental

Owner/Contact
Dr. Eric Brody/Mary Wachacha and Chris Lamer, PharmD

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. **GPRA Developmental:** Active CHD patients ages 22 and older, defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, AND at least 2 visits during the Report Period, AND 2 CHD-related visits ever.
   A. Active CHD patients ages 22 and older who are not Active Diabetic.
   B. Active CHD patients ages 22 and older who are Active Diabetic.

Numerators
1. Patients with Blood Pressure value documented at least twice in prior two years.
2. Patients with LDL completed during the Report Period, regardless of result.
3. Patients who have been screened for tobacco use during the Report Period.
4. Patients for whom a BMI could be calculated.
5. Patients who have received any lifestyle adaptation counseling, including medical nutrition therapy, or nutrition, exercise or other lifestyle education during the Report Period.
6. **GPRA Developmental:** Patients with comprehensive CVD assessment, defined as having BP, LDL, and tobacco use assessed, BMI calculated, and lifestyle counseling.

**Note:** This numerator does not include depression screening.

7. Patients screened for depression or diagnosed with a mood disorder or suicide ideation at any time during the Report Period.
Definitions

Diabetes
Diagnosed with diabetes (first POV in V POV with 250.00-250.93) prior to the Current Report period, AND at least 2 visits during the Current Report period, AND 2 DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

Coronary Heart Disease (CHD)
- 410.0-413.*, 414.0-414.9, or 429.2 recorded in the V POV file
- One or more CABG or PCI procedures, defined as any of the following:
  - CABG Procedure
    - CPT 33510-33514, 33516-33519, 33521-33523, 33533-33536;
    - Procedure 36.1* or 36.2*

Blood Pressure
Having a minimum of two BPs documented on non-ER visits in past two years. If CRS does not find 2 BPs, it will search for CPT 3074F-3080F documented on non-ER visit during the past 2 years.

LDL
Finds the most recent test done in the last 5 years, regardless of the results of the measurement.

LDL Definition
- CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
- LOINC taxonomy
- Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

Tobacco Screening
At least one of the following:
- Any health factor for category Tobacco documented during Current Report period
- Tobacco-related diagnoses (POV or current Active Problem List) 305.1, 305.1* (old codes), 649.00-649.04, or V15.82
- Dental code 1320
- Any patient education code containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, or V15.82
• CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455, G8456, G8457, G8402 or G8453

BMI
CRS calculates BMI at the time the report is run, using NHANES II. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.

Medical Nutrition Therapy
• CPT 97802-97804, G0270, G0271; Provider codes 07, 29
• Clinic codes 67 (dietary) or 36 (WIC)

Nutrition Education
• POV V65.3 dietary surveillance and counseling
• Patient education codes ending “-N” (Nutrition) or “-MNT” or containing V65.3 (or old code “-DT” (Diet))

Exercise Education
• POV V65.41 exercise counseling
• Patient education codes ending “-EX” (Exercise) or containing V65.41

Related Exercise and Nutrition Education
• Patient education codes ending “-LA” (lifestyle adaptation) or containing “OBS-” (obesity) or 278.00 or 278.01

Depression Screening/Mood Disorder or Suicide Ideation DX
Any of the following during the report period:

• Depression Screening
  – Exam Code 36
  – POV V79.0
  – BHS problem code 14.1 (screening for depression)
  – V Measurement in PCC or BH of PHQ2 or PHQ9

• Mood Disorder DX: At least two visits in PCC or BHS during the Report period with POV for:
  – Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.
    – These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; or BHS POV 14 or 15
• **Suicide Ideation DX**
  - POV V62.84; or
  - BHS Problem Code 39 during the Report Period

**Patient List Options**

List of Active CHD patients 22+ with a comprehensive CVD assessment.

List of Active CHD patients 22+ without a comprehensive CVD assessment.
2.6  STD-Related Group

2.6.1  HIV Screening

Moved from ONM to GPRA Developmental for 2010

Owner/Contact
Drs. Scott Giberson, Marie Russell, Jim Cheek, and John Redd

National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

Denominator
1. **GPRA Developmental:** User Population patients ages 13-64 with no recorded HIV diagnosis ever.

Numerators
1. **GPRA Developmental:** Patients who were screened for HIV during the Report Period.
2. Patients with documented HIV screening refusal during the Report Period.
   
   **Note:** This numerator does include refusals.
3. **GPRA Developmental:** Number of HIV screens provided to User Population patients during the Report Period, where the patient was not diagnosed with HIV anytime prior to the screen.

   **Note:** This numerator does not have a denominator. This measure is a total count only, not a percentage.

Definitions

HIV

Any of the following documented anytime prior to the end of the report period:
- POV or Problem List codes 042, 042.0-044.9 (old codes), 079.53, V08, or 795.71

HIV Screening
- CPT 86689, 86701-86703, 87390, 87391, 87534-87539
- LOINC taxonomy (added codes 49483-1, 49965-7, 51780-5, 51786-2, 51866-2, 53601-1, 56888-1, 57976-3, 57977-1, 57978-9)
- Site-populated taxonomy BGP HIV TESTS; or
• Refusal of any lab test in site-populated taxonomy BGP HIV TEST TAX

Note: Refusal is only included in the second numerator.

Patient List Options

List of User Population patients 13-64 with documented HIV test.


List of User Population patients with documented HIV test.
2.7 **High-Risk Medications Group**

2.7.1 **Use of High-Risk Medications in the Elderly**

*New GPRA Developmental, was previously reported in the Selected Measures report*

**Owner/Contact**
Dr. Bruce Finke

**National Reporting**
NATIONAL *(not included in IHS Performance Report; not reported to OMB in the PART Report)*

**Denominators**
1. **GPRA Developmental:** Active Clinical patients ages 65 and older, broken down by gender.

**Numerators**
2. **GPRA Developmental:** Patients who received at least one high-risk medication for the elderly during the Report Period.
3. **GPRA Developmental:** Patients who received at least two different high-risk medications for the elderly during the Report Period.

**Definitions**

**High-risk medications for the elderly (i.e., potentially harmful drugs)**
Defined with medication taxonomies:

| Note: For each medication, the days supply must be >0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the Medication Discontinued Date. Example: Rx Date=11/15/2006, Discontinued Date=11/19/2006, Recalculated # Days Prescribed=4. |

- **BGP HEDIS ANTIANXIETY MEDS**
  - (Includes combination drugs) (Aspirin-Meprobamate, Meprobamate)

- **BGP HEDIS ANTIEMETIC MEDS**
  - (Scopolamine, Trimethobenzamide)

- **BGP HEDIS ANALGESIC MEDS**
  - (Includes combination drugs) (Acetaminophen-diphenhydramine, diphenhydramine-magnesium salicylate, Ketorolac)

- **BGP HEDIS ANTIHISTAMINE MEDS**
(Includes combination drugs)

- **BGP HEDIS ANTIPSYCHOTIC MEDS**
  - (Thioridazine, Mesoridazine)

- **BGP HEDIS AMPHETAMINE MEDS**
  - (Amphetamine-dextroamphetamine, Benzphetamine, Dexmethylphenidate, Dextroamphetamine, Diethylpropion, Methamphetamine, Methylphenidate, Pemoline, Phendimetrazine, Phenteramine)

- **BGP HEDIS BARBITURATE MEDS**
  - (Amobarbital, Butabarbital, Meprobart, Pentobarbital, Phenobarbital, Secobarbital)

- **BGP HEDIS BENZODIAZEPINE MEDS**
  - (Includes combination drugs) (Amitriptyline-Chlordiazepoxide, Chlordiazepoxide, Chlordiazepoxide-clidinium, Diazepam, Flurazepam)

- **BGP HEDIS CALCIUM CHANNEL MEDS**
  - (Nifedipine - short acting only)

- **BGP HEDIS GASTRO ANTISPASM MED**
  - (Dicyclomine, Propantheline)

- **BGP HEDIS BELLADONNA ALKA MEDS**

- **BGP HEDIS SKL MUSCLE RELAX MED**
  - (Includes combination drugs) (ASA/caffeine/orphenadrine, ASA/carisoprodol/codeine, Aspirin-carisoprodol, Aspirin-meprobamate, Aspirin-methocarbamol, Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine)

- **BGP HEDIS ORAL ESTROGEN MEDS**
  - (Includes combination drugs) (Conjugated estrogen, Conjugated estrogen-medroxyprogesterone, Esterified estrogen, Esterified estrogen-methyltestosterone, Estropipate)

- **BGP HEDIS ORAL HYPOGLYCEMIC RX**
  - (Chlorpropamide)

- **BGP HEDIS NARCOTIC MEDS**
  - (Includes combination drugs) (ASA/caffeine/propoxyphene, Acetaminophen-pentazocine, Acetaminophen-propoxyphene, Belladonna-opium, Meperidine, Meperidine-promethazine, Naloxone-pentazocine, Pentazocine, Propoxyphene hydrochloride, Propoxyphene napsylate)

- **BGP HEDIS VASODILATOR MEDS**
  - (Cyclandelate, Dipyridamole-short acting only, Ergot mesyloid, Isoxsuprine)

- **BGP HEDIS OTHER MEDS AVOID ELD**
  - (Includes androgens and anabolic steroids, thyroid drugs, and urinary anti-infectives) (Methyltestosterone, Nitrofurantoin, Nitrofurantoin macrocrystals, Nitrofurantoin macrocrystals-monohydrate, Thyroid desiccated)

**Patient List Options**

- List of Active Clinical patients 65 and older with at least one high-risk medication for the elderly.

- List of Active Clinical patients 65 and older without at least one high-risk medication for the elderly.
3.0  **Contact Information**

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

**Phone:** (505) 248-4371 or (888) 830-7280 (toll free)

**Fax:** (505) 248-4363

**Web:** [http://www.ihs.gov/GeneralWeb/HelpCenter/Helpdesk/index.cfm](http://www.ihs.gov/GeneralWeb/HelpCenter/Helpdesk/index.cfm)

**Email:** support@ihs.gov